Cover Image
Market Research Report

Analyzing Generics Market in Japan 2017

Published by Aruvian's R'search Product code 482466
Published Content info 85 Pages
Delivery time: 1-2 business days
Price
Back to Top
Analyzing Generics Market in Japan 2017
Published: March 1, 2017 Content info: 85 Pages
Description

The development of the generic drugs sector in Japan has been a long standing plan of the Japanese government. The country has one of the highest healthcare costs amongst the G8 countries and the government has been focusing on developing the generics market in order to combat the rising healthcare and pharmaceutical costs. Due to this, the growth of the Japanese generics market does lag behind its peers countries.

Having experienced fluctuating growth in recent years, the Japanese generics industry has finally stabilized in terms of volume in the last year or so. The market's growth in terms of value is also expected to stabilize in the near future. The Japanese government plans to increase the share of the generics segment to nearly 80% of the total pharmaceutical market volume by the end of 2020.

Aruvian Research presents Analyzing Generics Market in Japan 2017 - a comprehensive coverage of the Japanese generic drugs market. Beginning with a sectional description on the global generic industry, the report looks at an overview of the industry, an analysis of the market volume and value, industry segmentation and an industry forecast.

Moving on, we analyze the Generics Industry in Asia Pacific through the same parameters.

The Generics Industry in Japan is analyzed through an industry overview which spans the data from 2012 till 2021. An analysis of the industry's value and volume data is included along with an industry segmentation by geography. Industry forecast of the industry is also included.

We also include a Porter's Five Forces analysis of the Japanese Generics Industry. Generics pricing and reimbursement situation in Japan and trends and challenges facing the industry are analyzed.

Analysis of the major industry players in the Japanese generics market are analyzed through an analysis of their business segments, a financial analysis and a SWOT analysis. Players analyzed include Daiichi Sankyo, Lupin, Sanofi SA, Teva Pharmaceutical Industries, Sawai Pharmaceutical Company and others. This concludes this comprehensive research report from Aruvian Research.

Table of Contents

Table of Contents

A. Executive Summary

B. Analyzing the Global Generics Industry

  • B.1. Industry Definition
  • B.2. Industry Overview
  • B.3. Industry Value & Volume Analysis
  • B.4. Industry Segmentation by Geography
  • B.5. Patent Expiries
  • B.6. Global Generic Industry Structure
  • B.7. Industry Forecast

C. Generics Industry in Asia Pacific

  • C.1. Industry Overview
  • C.2. Industry Value & Volume
  • C.3. Industry Segmentation by Geography
  • C.4. Industry Forecast

D. Generics Industry in Japan

  • D.1. Industry Overview
  • D.2. Industry Value & Volume
  • D.3. Industry Segmentation by Geography
  • D.4. Regulatory Framework
  • D.5. Industry Forecast

E. Generics Industry in Japan: Porter's Five Forces Strategy Analysis

  • E.1. Introduction
  • E.2. Bargaining Power of Buyers
  • E.3. Bargaining Power of Suppliers
  • E.4. Competitive Rivalry in the Industry
  • E.5. Threat of New Entrants
  • E.6. Threat of Substitutes

F. Pricing & Reimbursement in Japan

  • F.1. Overview
  • F.2. Generics Pricing & Reimbursement Scenario
  • F.3. Trends & Challenges

G. Major Industry Players

  • G.1. Allergan Plc
    • G.1.1. Corporate Analysis
    • G.1.2. Financial Analysis
    • G.1.3. SWOT Analysis
  • G.2. Daiichi Sankyo Co., Ltd.
    • G.2.1. Corporate Analysis
    • G.2.2. Financial Analysis
    • G.2.3. SWOT Analysis
  • G.3. Sanofi SA
    • G.3.1. Corporate Analysis
    • G.3.2. Financial Analysis
    • G.3.3. SWOT Analysis
  • G.4. Teva Pharmaceutical Industries Limited
    • G.4.1. Corporate Analysis
    • G.4.2. Financial Analysis
    • G.4.3. SWOT Analysis
  • G.5. Sawai Pharmaceutical Company Ltd

H. Glossary of Terms

List of Figures

  • Figure 1: Historical Revenues of Leading Generic Companies (in USD Million), 2008-2009
  • Figure 2: Growth of the Global Generics Industry by Value (in USD Billion), 2012-2016
  • Figure 3: Generics Percentage of Total Pharmaceutical Volume & Market Volume of Global Generics Industry (%), 2012-2016
  • Figure 4: Global Generics Market Segmentation by Geography (%), 2016
  • Figure 5: Revenues of Top 10 Drugs that went off Patent between 2010-2014 (in USD Million)
  • Figure 6: Market Share of Leading Generic Companies Worldwide (%), 2016
  • Figure 7: Comparison of Revenues of Leading Generic Companies (in USD Million), 2013-2014
  • Figure 8: Global Generics Industry Forecast (in USD Billion), 2016-2021
  • Figure 9: Global Generics Industry Forecast by Volume (% of Pharma Volume), 2016-2021
  • Figure 10: Value of the Asia Pacific Generics Market (in USD Billion), 2012-2016
  • Figure 11: Volume Growth of the Asia Pacific Generics Market (%), 2012-2016
  • Figure 12: Share of the Asia Pacific Generics Industry by Countries (%), 2016
  • Figure 13: Forecast of the Asia Pacific Generics Market (in USD Billion), 2016-2021
  • Figure 14: Volume Forecast of the Asia Pacific Generics Market (%), 2016-2021
  • Figure 15: Value of the Generics Market in Japan (in USD Billion), 2012-2016
  • Figure 16: Volume Growth of the Generics Market in Japan (%), 2012-2016
  • Figure 17: Share of Japan in the Asia Pacific Generics Industry (%), 2016
  • Figure 18: Forecast of the Generics Market in Japan (in USD Billion), 2016-2021
  • Figure 19: Volume Forecast of the Generics Market in Japan (%), 2016-2021
  • Figure 20: Porter's Five Forces Strategy Analysis of the Generics Industry in Japan
  • Figure 21: Bargaining Power of Buyers in the Japanese Generics Industry
  • Figure 22: Bargaining Power of Suppliers in the Japanese Generics Industry
  • Figure 23: Competitive Rivalry in the Japanese Generics Industry
  • Figure 24: Threat of New Entrants to the Japanese Generics Industry
  • Figure 25: Threat of Substitutes to the Japanese Generics Industry
  • Figure 26: Revenues & Profitability of Allergan Plc (in USD Million), 2011-2015
  • Figure 27: Revenues & Profitability of Daiichi Sankyo (in USD Million), 2011-2015
  • Figure 28: Revenues & Profitability of Sanofi SA (in USD Million), 2011-2015
  • Figure 29: Revenues & Profitability of Teva Pharmaceutical (in USD Million), 2011-2015
  • Figure 30: Revenues & Profitability of Sawai Pharmaceutical (in USD Million), 2011-2015

List of Tables

  • Table 1: Growth of the Global Generics Industry by Value (in USD Billion), 2012-2016
  • Table 2: Generics Percentage of Total Pharmaceutical Volume & Market Volume of Global Generics Industry (%), 2012-2016
  • Table 3: Global Generics Industry, Segmentation by Geography (in USD Billion), 2016
  • Table 4: Global Generics Industry Forecast (in USD Billion), 2016-2021
  • Table 5: Global Generics Industry Forecast by Volume & Percentage Growth (% of Pharma Volume), 2016-2021
  • Table 6: Value of the Asia Pacific Generics Market (in USD Billion), 2012-2016
  • Table 7: Volume Growth of the Asia Pacific Generics Market (%), 2012-2016
  • Table 8: Share of the Asia Pacific Generics Industry by Countries (% & USD Billion), 2016
  • Table 9: Forecast of the Asia Pacific Generics Market (in USD Billion), 2016-2021
  • Table 10: Volume Forecast of the Asia Pacific Generics Market (%), 2016-2021
  • Table 11: Value of the Generics Market in India (in USD Billion), 2012-2016
  • Table 12: Volume Growth of the Generics Market in India (%), 2012-2016
  • Table 13: Share of India in the Asia Pacific Generics Industry (in USD Billion & %), 2016
  • Table 14: Forecast of the Generics Market in Japan (in USD Billion), 2016-2021
  • Table 15: Volume Forecast of the Generics Market in Japan (%), 2016-2021
  • Table 16: Key Financials of Allergan Plc (in USD Million), 2011-2015
  • Table 17: Key Financials of Daiichi Sankyo (in USD Million), 2011-2015
  • Table 18: Key Financials of Sanofi SA (in USD Million), 2011-2015
  • Table 19: Key Financials of Teva Pharmaceutical (in USD Million), 2011-2015
  • Table 20: Key Financials of Sawai Pharmaceutical (in USD Million), 2011-2015
Back to Top